New risk index for COPD developed to estimate the risk of death

Researchers from the Centre for Research in Environmental Epidemiology (CREAL) and the Municipal Institute of Medical Research (IMIM-Hospital del Mar), in collaboration with the Hospital Clínic of Barcelona, have participated in an international consortium that has developed a new risk index for COPD patients. With this index, doctors can assess disease severity more objectively and estimate the risk of death.

According to Milo Puhan, researcher at the Johns Hopkins Bloomberg School of Public Health (USA) from the University of Zurich (Switzerland) and coordinator of the international consortium that has conducted the study, "Now it will be possible to adjust the treatment according to the underlying risk of mortality, as cardiologists have already done for a long time in patients with cardiovascular disease".

Chronic obstructive pulmonary disease (COPD)

Although this term may not be familiar to many, COPD is among the five leading causes of death worldwide, killing three million people each year. The disease affects almost half of smokers during their lifetime. In Spain, it is estimated that more than 18,000 people die each year from this disease. It is the fifth leading cause of death in men (60 deaths for every 100,000 inhabitants) and the seventh leading cause in women (17 deaths for every 100,000 inhabitants). Nevertheless, these figures increase year after year in Spain, as our country has the highest rate of adolescent smoking in Europe and one of the highest percentages of women smokers in the world. 

Inflammation in the lungs and the rest of the body, together with progressive shortness of breath, cause suffocation, one of the main problems in patients' daily lives. "Presently, most patients receive similar treatment. This is partly due to the traditional assessment of disease severity, which is based only on lung function and does not predict the clinical conditions or progressive course of the disease with much precision" states Judith Garcia-Aymerich, Spanish coordinator of the study and researcher from CREAL and IMIM-Hospital del Mar. To arrive at this conclusion, the international research consortium analysed data from 232 Swiss patients from the Barmelweid cohort and 342 Spanish patients from the Phenotype Characterisation and Course of COPD (PAC-COPD) cohort, which includes COPD patients from five hospitals in Catalonia, one in the Basque Country and one in the Balearic Islands.

Simplified risk index

The current issue of The Lancet (*) presents, for the first time, an index which can easily be used in primary care settings, where most COPD patients are treated. The ADO Index (age, dyspnoea, obstruction) considers, besides lung function, the patients' age and their level of dyspnoea. It predicts the probability that an individual patient will die within the next three years.

"This simple and practical index explicitly indicates the risk of mortality for an individual patient and helps identify patients who may benefit from a more comprehensive and individualised treatment", adds Garcia-Aymerich. Besides quitting smoking and the use of inhaled drugs, there are highly-effective non-pharmacological treatments such as pulmonary rehabilitation and regular physical exercise. The Spanish researchers heading this study continue to analyse how COPD progresses over time and how this progression can be modified.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates